Sulfonylureas and Cardiovascular Safety – The Final Verdict?
Wexler DJ
JAMA. 2019;322(12):1147-49
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Use of Fenofibrate On Cardiovascular Outcomes in Statin Users with Metabolic Syndrome: Propensity Matched Cohort Study
Kim NH, Han KH, Choi J, et al.
BMJ 2019;366 :l5125
Leggi
Cardiovascular Corner – Prescription Omega-3s, Stroke Rehab, and Statins After Age 75
Abbasi J
JAMA. Pub. online 11 September 2019
Leggi
Association of Metabolic Surgery with Major Adverse Cardiovascular Outcomes in Patients with Type 2 Diabetes and Obesity
Aminian A, Zajichek A,Arterburn DE, et al.
JAMA. Pub. online 2 September 2019
Leggi
Lipid-Lowering Prescription Patterns in Patients with Diabetes Mellitus or Cardiovascular Disease
Chamberlain AM, Cohen SS, Killian JM, et al.
Am J Cardiol. 2019;124(7):995-1001
Leggi
Trends in Incidence of Total or Type 2 Diabetes: Systematic Review
Magliano DJ, Islam RM, Barr ELM, et al.
BMJ 2019;366:l5003
Leggi
Environmental neglect: endocrine disruptors as underappreciated but potentially modifiable diabetes risk factors
Sargis RM, Simmons RA
Diabetologia. 2019,62:1811-22
Leggi
Risks of ischaemic heart disease and stroke in meat eaters, fish eaters, and vegetarians over 18 years of follow-up: results from the prospective EPIC-Oxford study
Tong TYN, Appleby PN, Bradbury KE, et al.
BMJ. 2019;366:l4897
Leggi
The diabesity epidemic in the light of evolution: insights from the capacity–load model
Wells JCK
Diabetologia. 2019,62:1740-50
Leggi
Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course
Huebschmann AG, Huxley RR, Kohrt WM, et al.
Diabetologia. 2019, 62:1761–1772
Leggi